Journal article · 2021 · Open access

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Quintín Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso and 22 more

New England Journal of Medicine, 386(6), 531–543 · Published 15 December 2021 · DOI 10.1056/nejmoa2116185

Open PDFView at the publisherCite this paper

In brief

“Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico” is a 2021 journal article by Lisa M. Dunkle and 33 co-authors, published in New England Journal of Medicine. OpenAlex counts 466 citations as of 20 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access: the full text is free to read at medRxiv.

Citations
466
Most cited in
2022 (136)
Field-weighted impact
28.08
References
17
Authors
34

Abstract

BACKGROUND: NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America. METHODS: We conducted a phase 3, randomized, observer-blinded, placebo-controlled trial in the United States and Mexico during the first half of 2021 to evaluate the efficacy and safety of NVX-CoV2373 in adults (≥18 years of age) who had not had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Participants were randomly assigned in a 2:1 ratio to receive two doses of NVX-CoV2373 or placebo 21 days apart. The primary objective was to determine vaccine efficacy against reverse-transcriptase-polymerase-chain-reaction-confirmed Covid-19 occurring at least 7 days after the second dose. Vaccine efficacy against moderate-to-severe disease and against different variants was also assessed. RESULTS: Of the 29,949 participants who underwent randomization between December 27, 2020, and February 18, 2021, a total of 29,582 (median age, 47 years; 12.6% ≥65 years of age) received at least one dose: 19,714 received vaccine and 9868 placebo. Over a period of 3 months, 77 cases of Covid-19 were noted - 14 among vaccine recipients and 63 among placebo recipients (vaccine efficacy, 90.4%; 95% confidence interval [CI], 82.9 to 94.6; P<0.001). Ten moderate and 4 severe cases occurred, all in placebo recipients, yielding vaccine efficacy against moderate-to-severe disease of 100% (95% CI, 87.0 to 100). Most sequenced viral genomes (48 of 61, 79%) were variants of concern or interest - largely B.1.1.7 (alpha) (31 of the 35 genomes for variants of concern, 89%). Vaccine efficacy against any variant of concern or interest was 92.6% (95% CI, 83.6 to 96.7). Reactogenicity was mostly mild to moderate and transient but was more frequent among NVX-CoV2373 recipients than among placebo recipients and was more frequent after the second dose than after the first dose. CONCLUSIONS: NVX-CoV2373 was safe and effective for the prevention of Covid-19. Most breakthrough cases were caused by contemporary variant strains. (Funded by Novavax and others; PREVENT-19 ClinicalTrials.gov number, NCT04611802.).

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Dunkle, L. M., Kotloff, K. L., Gay, C. L., Áñez, G., Adelglass, J. M., Hernández, A. Q. B., Harper, W. L., Duncanson, D. M., McArthur, M. A., Florescu, D. F., McClelland, R. S., Garcia-Fragoso, V., Riesenberg, R. A., Musante, D. B., Fried, D. L., Safirstein, B., McKenzie, M., Jeanfreau, R. J., Kingsley, J. K., . . . for the 2019nCoV-301 Study Group. (2021). Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. New England Journal of Medicine, 386(6), 531–543. https://doi.org/10.1056/nejmoa2116185

MLA 9

Dunkle, Lisa M., et al. “Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.” New England Journal of Medicine, vol. 386, no. 6, 2021, pp. 531–543. https://doi.org/10.1056/nejmoa2116185.

Chicago

Dunkle, Lisa M., Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Quintín Barrat Hernández, Wayne L. Harper, et al. 2021. “Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.” New England Journal of Medicine 386 (6): 531–543. https://doi.org/10.1056/nejmoa2116185.

Harvard

Dunkle, L. M. et al. (2021) ‘Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico’, New England Journal of Medicine, 386(6), pp. 531–543. doi:10.1056/nejmoa2116185.

IEEE

L. M. Dunkle et al., “Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico,” New England Journal of Medicine, vol. 386, no. 6, pp. 531–543, 2021, doi: 10.1056/nejmoa2116185.

BibTeX

@article{dunkle2021efficacy,
  title     = {{Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico}},
  author    = {Dunkle, Lisa M. and Kotloff, Karen L. and Gay, Cynthia L. and Áñez, Germán and Adelglass, Jeffrey M. and Hernández, Alejandro Quintín Barrat and Harper, Wayne L. and Duncanson, Daniel M. and McArthur, Monica A. and Florescu, Diana F. and McClelland, R. Scott and Garcia-Fragoso, Veronica and Riesenberg, Robert A. and Musante, David B. and Fried, David L. and Safirstein, Beth and McKenzie, Mark and Jeanfreau, Robert J. and Kingsley, Jeffrey K. and Henderson, Jeffrey A. and Lane, Dakotah C. and Ruiz-Palacios, Guillermo Miguel and Corey, Lawrence and Neuzil, Kathleen Maletic and Coombs, Robert W. and Greninger, Alexander L. and Hütter, Julia and Ake, Julie A. and Smith, Katherine and Woo, Wayne and others},
  journal   = {New England Journal of Medicine},
  year      = {2021},
  volume    = {386},
  number    = {6},
  pages     = {531--543},
  doi       = {10.1056/nejmoa2116185},
  url       = {https://doi.org/10.1056/nejmoa2116185}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202133
2022136136
2023130130
20248888
20257272
20263737

Its field-weighted citation impact is 28.08: it has been cited 28.08 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • COVID-19 vaccines
  • vaccine efficacy
  • vaccine safety
  • SARS-CoV-2 variants of concern
  • B.1.1.7 Alpha variant
  • B.1.617.2 Delta variant
  • Omicron variant

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Dunkle, L. M., Kotloff, K. L., Gay, C. L., Áñez, G., Adelglass, J. M., Hernández, A. Q. B., Harper, W. L., Duncanson, D. M., McArthur, M. A., Florescu, D. F., McClelland, R. S., Garcia-Fragoso, V., Riesenberg, R. A., Musante, D. B., Fried, D. L., Safirstein, B., McKenzie, M., Jeanfreau, R. J., Kingsley, J. K., . . . for the 2019nCoV-301 Study Group. (2021). Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. New England Journal of Medicine, 386(6), 531–543. https://doi.org/10.1056/nejmoa2116185

How many times has this paper been cited?

466 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at medRxiv: sign in and open the PDF from this page.

Who wrote this paper?

Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Quintín Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso and 22 more.

What is the DOI of this paper?

10.1056/nejmoa2116185, permanently at https://doi.org/10.1056/nejmoa2116185. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.